Department of Anaesthesia and Critical Care Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.
Intensive Care Med. 2010 Aug;36(8):1380-5. doi: 10.1007/s00134-010-1836-2. Epub 2010 Mar 18.
We compared 1 versus 0.5 microg/kg bolus remifentanil versus placebo in alleviating pain due to chest drain removal. Effects on sedation, respiratory rate (RR), oxygen saturation, heart rate (HR) and blood pressure were also evaluated.
Sixty patients following cardiac surgery were enrolled in this prospective, randomized, double-blind clinical trial. Patients were randomized to 1 or 0.5 microg/kg remifentanil or placebo. All received standardized analgesia. Visual analog scale (VAS) pain scores and cardio-respiratory data were recorded pre-procedure, at drain removal and at 2 min intervals post procedure.
Patients receiving remifentanil had statistically significantly less pain than placebo at drain removal [median (25-75%) VAS: 0.5 microg/kg remifentanil 1 (0-2) versus placebo 5 (3-6), P = 0.001; 1.0 microg/kg remifentanil 0 (0-2) versus placebo 5 (3-6), P = 0.0001]. VAS scores between remifentanil groups were equivalent. Remifentanil 1 microg/kg versus placebo at drain removal revealed significant reductions in HR [mean +/- standard deviation (SD): 76 +/- 15 versus 92 +/- 10, P = 0.01], blood pressure [mean +/- SD: 103 +/- 22 versus 131 +/- 14, P = 0.01] and RR [median (25-75%): 10 (8-12) versus 16 (14-18), P = 0.001]. Remifentanil 0.5 microg/kg versus placebo at drain removal revealed significant reductions in blood pressure [mean +/- SD: 116 +/- 19 versus 131 +/- 14, P = 0.02] and RR [median (25-75%): 12 (10-13) versus 18 (16-18), P = 0.001]. SpO(2) at drain removal was significantly reduced when comparing 1 microg/kg remifentanil versus placebo [median (25-75%): 94 (88-97) versus 97 (96-98), P = 0.049] but not 0.5 microg/kg remifentanil versus placebo. Two patients became apnoeic following 1 microg/kg remifentanil, necessitating respiratory support. Sedation scores in all groups were similar.
Bolus remifentanil at the tested doses delivers excellent analgesia, but 1 microg/kg remifentanil results in respiratory depression. Remifentanil bolus at 0.5 microg/kg is safe and effective for chest drain removal after heart surgery in ICU.
我们比较了 1 微克/千克与 0.5 微克/千克瑞芬太尼推注与安慰剂在缓解胸腔引流管移除疼痛方面的效果。还评估了镇静、呼吸频率(RR)、血氧饱和度、心率(HR)和血压的影响。
本前瞻性、随机、双盲临床试验纳入了 60 名心脏手术后的患者。患者被随机分配至 1 微克/千克或 0.5 微克/千克瑞芬太尼或安慰剂组。所有患者均接受标准化镇痛。在术前、引流管移除时和术后 2 分钟间隔记录视觉模拟量表(VAS)疼痛评分和心肺数据。
与安慰剂相比,接受瑞芬太尼的患者在引流管移除时疼痛明显减轻[中位数(25-75%)VAS:0.5 微克/千克瑞芬太尼 1(0-2)与安慰剂 5(3-6),P=0.001;1.0 微克/千克瑞芬太尼 0(0-2)与安慰剂 5(3-6),P=0.0001]。瑞芬太尼组之间的 VAS 评分相当。与安慰剂相比,瑞芬太尼 1 微克/千克在引流管移除时 HR[均值±标准差(SD):76±15 与 92±10,P=0.01]、血压[均值±SD:103±22 与 131±14,P=0.01]和 RR[中位数(25-75%):10(8-12)与 16(14-18),P=0.001]明显降低。与安慰剂相比,瑞芬太尼 0.5 微克/千克在引流管移除时血压[均值±SD:116±19 与 131±14,P=0.02]和 RR[中位数(25-75%):12(10-13)与 18(16-18),P=0.001]明显降低。与安慰剂相比,瑞芬太尼 1 微克/千克在引流管移除时 SpO2[中位数(25-75%):94(88-97)与 97(96-98),P=0.049]明显降低,但瑞芬太尼 0.5 微克/千克组无此变化。与安慰剂相比,1 微克/千克瑞芬太尼组有 2 名患者出现呼吸暂停,需要呼吸支持。所有组的镇静评分相似。
测试剂量的瑞芬太尼推注可提供良好的镇痛效果,但 1 微克/千克瑞芬太尼可导致呼吸抑制。瑞芬太尼 0.5 微克/千克推注用于 ICU 心脏手术后胸腔引流管移除是安全有效的。